

Effectiveness of Care Measure

# Osteoporosis Management in Women Who Had a Fracture



Learn how to improve your Healthcare Effectiveness Data and Information Set (HEDIS®) rates by using this tip sheet about the Osteoporosis Management in Women Who Had a Fracture (OMW) measure, best practices and more resources.

<p><b>Measure</b></p>	<p>Women ages 67–85 who suffered a fracture and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.</p> <p>Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:</p> <ul style="list-style-type: none"> <li>• A BMD test within 6 months/180 days of the fracture, or</li> <li>• Osteoporosis therapy or a dispensed prescription to treat osteoporosis that's filled within 6 months/180 days of the fracture.</li> </ul>
<p><b>Exclusions</b></p>	<p>Patients who meet the following criteria:</p> <ul style="list-style-type: none"> <li>• Patient who had a BMD test within 24 months preceding the fracture.</li> <li>• Patients with a fracture of a finger, toe, face, or skull.</li> <li>• Patients who received a dispensed prescription or had an active prescription to treat osteoporosis within the 12 months preceding the fracture.</li> <li>• Patients who had a fracture within 60 days preceding the fracture.</li> <li>• Patients enrolled in an institutional SNP (I-SNP) or living long-term in an institution from July 1 of the prior year through the end of the measurement year.</li> <li>• Patients with advanced illness and frailty from July 1 of the prior year through the end of the measurement year.</li> <li>• Patients in hospice.</li> </ul>
<p><b>Best practices</b></p>	<ul style="list-style-type: none"> <li>• Ask patients whether they have had a fracture since the last appointment.</li> <li>• Evaluate women for risk factors that would increase the risk of osteoporosis. Some risk factors include low body weight, excessive alcohol intake, current tobacco use, history of fractures, and use of certain medications.</li> <li>• Refer patients to case management for resources and help with post-fracture.</li> <li>• Set up a process to identify patients with fractures and notify the primary care physician (PCP) to ensure BMD test is completed in a timely manner.</li> <li>• Prescribe medication to treat osteoporosis.</li> <li>• Discuss osteoporosis prevention with your patients, such as taking calcium and vitamin D supplements, and taking part in weight-bearing exercises.</li> <li>• Promote evidence-based interventions, such as Fracture Liaison Services (FLS), coordinator-based, secondary fracture prevention services for the systemic identification and treatment of osteoporotic patients.</li> </ul>



Often called a silent disease, osteoporosis reduces bone mass through structural deterioration, resulting in compromised bone strength. Osteoporosis is more common in women than in men. One in two women will have an osteoporosis-related fracture in their lifetime.<sup>1</sup>

(continued)

<sup>1</sup>National Osteoporosis Foundation. What is Osteoporosis and What Causes It. Retrieved from [www.nof.org/patients/what-is-osteoporosis/](http://www.nof.org/patients/what-is-osteoporosis/). August 5, 2019.

<b>CPT codes</b>	<b>Use the appropriate service codes when billing for OMW screenings</b>	
	Bone mineral density tests	<b>CPT code</b> 76977, 77078, 77080-77082, 77085, 77086
		<b>ICD-10-PCS</b> BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZ1, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BRO0ZZ1, BR07ZZ1, BRO9ZZ1, BROGZZ1
Osteoporosis therapy	<b>HCPCS</b> J0897, J1740, J3110, J3489	

<b>Medications</b>	<b>Prescribe the appropriate medications for OMW</b>	
	<b>Description</b>	<b>Medication</b>
	Bisphosphonates	<ul style="list-style-type: none"> <li>• Alendronate</li> <li>• Alendronate-cholecalciferol</li> <li>• Risedronate</li> <li>• Zoledronic acid</li> <li>• Ibandronate</li> </ul>
Other agents	<ul style="list-style-type: none"> <li>• Abaloparatide</li> <li>• Denosumab</li> <li>• Raloxifene</li> <li>• Teriparatide</li> </ul>	

#### Resources

- National Osteoporosis Foundation. What is Osteoporosis and What Causes It. Retrieved from [www.nof.org/patients/what-is-osteoporosis/](http://www.nof.org/patients/what-is-osteoporosis/), August 5, 2019.
- Final Recommendation Statement: Osteoporosis to Prevent Fractures: Screening. USPSTF. July 2019. Retrieved from: [www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/osteoporosis-screening1](http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/osteoporosis-screening1), August 5, 2019.
- National Committee for Quality Assurance (NCQA) HEDIS 2020 Technical Specifications for Health Plans, Volume 2. Washington, D.C., 2019.

Health Net of California, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.